UNSPSC 51372207: Dextromoramide tartrate

This classification denotes an opioid receptor agonist with the molecular formula C25H32N2O2.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J778U505W5, chemically known as pyrrolidine, 1-(3-methyl-4-morpholino-2,2-diphenylbutyryl)-, (+)-, tartrate (1:1) but more generally known as dextromoramide tartrate, which bears US NIH Compound Identifier 92942. European Medicines Agency schedules Dextromoramide tartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01647MIG.

UNSPSC 51372207 Dextromoramide tartrate is a Commodity code that in practice covers pharmaceutical procurement by state and local health agencies, though recent state and local opportunities show little direct solicitation under this specific opioid code itself. State and local governments soliciting under related pharmaceutical codes are buying naloxone, generic multi-source pharmaceuticals, over-the-counter products, and related public health and pharmacy benefit management services. The issuing bodies include county health departments (such as Seminole County, Florida), state health and human services agencies (such as the Texas Health and Human Services Commission), and cooperative purchasing alliances (such as the Minnesota Multistate Cooperative Purchasing Alliance). Vendors in this space must meet cGMP and Drug Supply Chain Security Act compliance, maintain relationships with authorized wholesalers, hold appropriate insurance coverage, and comply with federal requirements including E-Verify and clean-air and water-quality regulations.

Recent state and local activity under related pharmaceutical codes spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 (with response due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program that would establish direct relationships between the state pharmacy benefit program and manufacturers outside existing pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 (posted January 20, 2026, response due March 26, 2026) for multiple contracts covering generic multi-source pharmaceuticals and over-the-counter products, with awards to take effect July 1, 2026 and pricing evaluated at 75 percent weight against compliance, administrative capability, and fixed-term pricing factors.